Your browser doesn't support javascript.
loading
Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Kelly, Christabel; Swadling, Leo; Capone, Stefania; Brown, Anthony; Richardson, Rachel; Halliday, John; von Delft, Annette; Oo, Ye; Mutimer, David; Kurioka, Ayako; Hartnell, Felicity; Collier, Jane; Ammendola, Virginia; Del Sorbo, Mariarosaria; Grazioli, Fabiana; Esposito, Maria Luisa; Di Marco, Stefania; Siani, Loredana; Traboni, Cinzia; Hill, Adrian V S; Colloca, Stefano; Nicosia, Alfredo; Cortese, Riccardo; Folgori, Antonella; Klenerman, Paul; Barnes, Eleanor.
Afiliação
  • Kelly C; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Swadling L; Oxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
  • Capone S; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Brown A; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Richardson R; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Halliday J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • von Delft A; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Oo Y; Oxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
  • Mutimer D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Kurioka A; Department of Hepatology, Queen Elizabeth Hospital, Birmingham, UK.
  • Hartnell F; Department of Hepatology, Queen Elizabeth Hospital, Birmingham, UK.
  • Collier J; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Ammendola V; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Del Sorbo M; Oxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
  • Grazioli F; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Esposito ML; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Di Marco S; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Siani L; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Traboni C; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Hill AV; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Colloca S; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Nicosia A; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cortese R; The Jenner Institute, University of Oxford, Oxford, UK.
  • Folgori A; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
  • Klenerman P; Oxford NIHR BRC and Translational Gastroenterology Unit, Oxford, UK.
  • Barnes E; ReiThera Srl (formerly Okairos Srl), Viale Città d'Europa, Rome, Italy.
Hepatology ; 63(5): 1455-70, 2016 May.
Article em En | MEDLINE | ID: mdl-26474390
UNLABELLED: Adenoviral vectors encoding hepatitis C virus (HCV) nonstructural (NS) proteins induce multispecific, high-magnitude, durable CD4(+) and CD8(+) T-cell responses in healthy volunteers. We assessed the capacity of these vaccines to induce functional HCV-specific immune responses and determine T-cell cross-reactivity to endogenous virus in patients with chronic HCV infection. HCV genotype 1-infected patients were vaccinated using heterologous adenoviral vectors (ChAd3-NSmut and Ad6-NSmut) encoding HCV NS proteins in a dose escalation, prime-boost regimen, with and without concomitant pegylated interferon-α/ribavirin therapy. Analysis of immune responses ex vivo used human leukocyte antigen class I pentamers, intracellular cytokine staining, and fine mapping in interferon-γ enzyme-linked immunospot assays. Cross-reactivity of T cells with population and endogenous viral variants was determined following viral sequence analysis. Compared to healthy volunteers, the magnitude of HCV-specific T-cell responses following vaccination was markedly reduced. CD8(+) HCV-specific T-cell responses were detected in 15/24 patients at the highest dose, whereas CD4(+) T-cell responses were rarely detectable. Analysis of the host circulating viral sequence showed that T-cell responses were rarely elicited when there was sequence homology between vaccine immunogen and endogenous virus. In contrast, T cells were induced in the context of genetic mismatch between vaccine immunogen and endogenous virus; however, these commonly failed to recognize circulating epitope variants and had a distinct partially functional phenotype. Vaccination was well tolerated but had no significant effect on HCV viral load. CONCLUSION: Vaccination with potent HCV adenoviral vectored vaccines fails to restore T-cell immunity except where there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the major challenge of overcoming T-cell exhaustion in the context of persistent antigen exposure with implications for cancer and other persistent infections.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Hepatite Viral / Linfócitos T / Hepacivirus / Hepatite C Crônica Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Hepatite Viral / Linfócitos T / Hepacivirus / Hepatite C Crônica Limite: Adult / Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article